{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,27]],"date-time":"2026-03-27T18:06:59Z","timestamp":1774634819876,"version":"3.50.1"},"reference-count":98,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,11,15]],"date-time":"2021-11-15T00:00:00Z","timestamp":1636934400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Endocrinol."],"abstract":"<jats:p>Management of aggressive pituitary adenomas is challenging due to a paucity of rigorous evidence supporting available treatment approaches. Recent guidelines emphasize the need to maximize standard therapies as well as the use of temozolomide and radiation therapy to treat disease recurrence. However, often these adenomas continue to progress over time, necessitating the use of additional targeted therapies which also impact quality of life and long-term outcomes. In this review, we present 9 cases of aggressive pituitary adenomas to illustrate the importance of a multidisciplinary, individualized approach. The timing and rationale for surgery, radiation therapy, temozolomide, somatostatin receptor ligands, and EGFR, VEGF, and mTOR inhibitors in each case are discussed within the context of evidence-based guidelines and clarify strategies for implementing an individualized approach in the management of these difficult-to-treat-adenomas.<\/jats:p>","DOI":"10.3389\/fendo.2021.725014","type":"journal-article","created":{"date-parts":[[2021,11,15]],"date-time":"2021-11-15T06:33:43Z","timestamp":1636958023000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":10,"title":["Treatment of Aggressive Pituitary Adenomas: A Case-Based Narrative Review"],"prefix":"10.3389","volume":"12","author":[{"given":"Odelia","family":"Cooper","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vivien","family":"Bonert","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ning-Ai","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adam N.","family":"Mamelak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2021,11,15]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1007\/s00401-017-1769-8","article-title":"The 2017 World Health Organization Classification of Tumors of the Pituitary Gland: A Summary","volume":"134","author":"Lopes","year":"2017","journal-title":"Acta Neuropathol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1810772","article-title":"Pituitary-Tumor Endocrinopathies","volume":"382","author":"Melmed","year":"2020","journal-title":"N Engl J Med"},{"key":"B3","doi-asserted-by":"publisher","first-page":"G1","DOI":"10.1530\/EJE-17-0796","article-title":"European Society of Endocrinology Clinical Practice Guidelines for the Management of Aggressive Pituitary Tumours and Carcinomas","volume":"178","author":"Raverot","year":"2018","journal-title":"Eur J Endocrinol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1007\/s11102-017-0838-2","article-title":"Criteria for the Definition of Pituitary Tumor Centers of Excellence (PTCOE): A Pituitary Society Statement","volume":"20","author":"Casanueva","year":"2017","journal-title":"Pituitary"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2010-1692","article-title":"Diagnosis and Treatment of Hyperprolactinemia: An Endocrine Society Clinical Practice Guideline","volume":"96","author":"Melmed","year":"2011","journal-title":"J Clin Endocrinol Metab"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2007-2758","article-title":"Prospective Study of High-Dose Cabergoline Treatment of Prolactinomas in 150 Patients","volume":"93","author":"Ono","year":"2008","journal-title":"J Clin Endocrinol Metab"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2015-1818","article-title":"Treatment of Cushing's Syndrome: An Endocrine Society Clinical Practice Guideline","volume":"100","author":"Nieman","year":"2015","journal-title":"J Clin Endocrinol Metab"},{"key":"B8","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1007\/s11102-009-0195-x","article-title":"Endoscopic Endonasal Transsphenoidal Surgery: Surgical Results of 228 Pituitary Adenomas Treated in a Pituitary Center","volume":"13","author":"Gondim","year":"2010","journal-title":"Pituitary"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1159\/000095533","article-title":"Transsphenoidal Microsurgery for Newly Diagnosed Acromegaly: A Personal View After More Than 1,000 Operations","volume":"83","author":"Ludecke","year":"2006","journal-title":"Neuroendocrinology"},{"key":"B10","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1007\/s11102-012-0437-1","article-title":"Single-Surgeon Fully Endoscopic Endonasal Transsphenoidal Surgery: Outcomes in Three-Hundred Consecutive Cases","volume":"16","author":"Mamelak","year":"2013","journal-title":"Pituitary"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1530\/eje.1.02334","article-title":"The Natural Course of Non-Functioning Pituitary Macroadenomas","volume":"156","author":"Dekkers","year":"2007","journal-title":"Eur J Endocrinol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2005-2552","article-title":"Observation Alone After Transsphenoidal Surgery for Nonfunctioning Pituitary Macroadenoma","volume":"91","author":"Dekkers","year":"2006","journal-title":"J Clin Endocrinol Metab"},{"key":"B13","doi-asserted-by":"publisher","first-page":"321","DOI":"10.3171\/2019.3JNS19121","article-title":"Prolactinomas and Nonfunctioning Adenomas: Preoperative Diagnosis of Tumor Type Using Serum Prolactin and Tumor Size","volume":"133","author":"Burke","year":"2020","journal-title":"J Neurosurg"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2265.2002.01511.x","article-title":"Long-Term Follow-Up Results of Transsphenoidal Surgery for Cushing's Disease in a Single Centre Using Strict Criteria for Remission","volume":"56","author":"Rees","year":"2002","journal-title":"Clin Endocrinol (Oxf)"},{"key":"B15","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1007\/s11102-011-0347-7","article-title":"Clinical Factors Involved in the Recurrence of Pituitary Adenomas After Surgical Remission: A Structured Review and Meta-Analysis","volume":"15","author":"Roelfsema","year":"2012","journal-title":"Pituitary"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.3171\/jns.2005.102.6.1004","article-title":"Repeated Transsphenoidal Surgery to Treat Recurrent or Residual Pituitary Adenoma","volume":"102","author":"Benveniste","year":"2005","journal-title":"J\u00a0Neurosurg"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1507\/endocrj.50.635","article-title":"Effectiveness of Secondary Transnasal Surgery in GH-Secreting Pituitary Macroadenomas","volume":"50","author":"Kurosaki","year":"2003","journal-title":"Endocr J"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.3171\/2017.2.JNS162673","article-title":"Reoperation for Growth Hormone-Secreting Pituitary Adenomas: Report on an Endonasal Endoscopic Series With a Systematic Review and Meta-Analysis of the Literature","volume":"129","author":"Almeida","year":"2018","journal-title":"J Neurosurg"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1007\/s12094-018-1868-6","article-title":"Recurrent Non-Functioning Pituitary Adenomas: A Review on the New Pathological Classification, Management Guidelines and Treatment Options","volume":"20","author":"Delgado-Lopez","year":"2018","journal-title":"Clin Transl Oncol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1530\/EJE-18-0291","article-title":"MRI Texture Analysis as a Predictor of Tumor Recurrence or Progression in Patients With Clinically Non-Functioning Pituitary Adenomas","volume":"179","author":"Galm","year":"2018","journal-title":"Eur J Endocrinol"},{"key":"B21","article-title":"Relationship Between Pituitary Adenoma Texture and Collagen Content Revealed by Comparative Study of MRI and Pathology Analysis","volume":"8","author":"Wei","year":"2015","journal-title":"Int J Clin Exp Med"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1007\/s11060-018-2801-0","article-title":"Debulking Surgery of Pituitary Adenoma as a Strategy to Facilitate Definitive Stereotactic Radiosurgery","volume":"138","author":"Forster","year":"2018","journal-title":"J Neurooncol"},{"key":"B23","doi-asserted-by":"publisher","first-page":"101269","DOI":"10.1016\/j.beem.2019.04.003","article-title":"The Risk\/Benefit Ratio of Radiotherapy in Pituitary Tumors","volume":"33","author":"Minniti","year":"2019","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"key":"B24","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1016\/j.wneu.2019.11.041","article-title":"Effect of Stereotactic Radiosurgery on Residual or Relapsed Pituitary Adenoma: A Systematic Review and Meta-Analysis","volume":"136","author":"Heringer","year":"2020","journal-title":"World Neurosurg"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.3171\/jns.2005.102.4.0678","article-title":"Stereotactic Radiosurgery for Pituitary Adenomas: An Intermediate Review of Its Safety, Efficacy, and Role in the Neurosurgical Treatment Armamentarium","volume":"102","author":"Sheehan","year":"2005","journal-title":"J Neurosurg"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1210\/jc.83.10.3419","article-title":"Long-Term Mortality After Transsphenoidal Surgery and Adjunctive Therapy for Acromegaly","volume":"83","author":"Swearingen","year":"1998","journal-title":"J Clin Endocrinol Metab"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.3171\/jns.1995.82.4.0536","article-title":"Low-Grade Gliomas of the Cerebral Hemispheres in Children: An Analysis of 71 Cases","volume":"82","author":"Pollack","year":"1995","journal-title":"J\u00a0Neurosurg"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1007\/s11060-013-1262-8","article-title":"Treatment Paradigms for Pituitary Adenomas: Defining the Roles of Radiosurgery and Radiation Therapy","volume":"117","author":"Ding","year":"2014","journal-title":"J\u00a0Neurooncol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2017-01385","article-title":"Stereotactic Radiosurgery for Cushing Disease: Results of an International, Multicenter Study","volume":"102","author":"Mehta","year":"2017","journal-title":"J Clin Endocrinol Metab"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1038\/nrendo.2011.12","article-title":"Management of Cushing Disease","volume":"7","author":"Tritos","year":"2011","journal-title":"Nat Rev Endocrinol"},{"key":"B31","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1227\/01.NEU.0000043709.53906.31","article-title":"Radiation Tolerance of Functioning Pituitary Tissue in Gamma Knife Surgery for Pituitary Adenomas","volume":"52","author":"Vladyka","year":"2003","journal-title":"Neurosurgery"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1007\/s11060-019-03296-8","article-title":"Safety and Efficacy of Repeat Radiosurgery for Acromegaly: An International Multi-Institutional Study","volume":"145","author":"Alonso","year":"2019","journal-title":"J Neurooncol"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1016\/0360-3016(92)90686-C","article-title":"Re-Irradiation of Pituitary Adenoma","volume":"24","author":"Schoenthaler","year":"1992","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1007\/s11154-020-09551-y","article-title":"Temozolomide Therapy for Aggressive Pituitary Tumours - Current Understanding and Future Perspectives","volume":"21","author":"Burman","year":"2020","journal-title":"Rev Endocr Metab Disord"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1530\/ERC-19-0083","article-title":"How and When to Use Temozolomide to Treat Aggressive Pituitary Tumours","volume":"26","author":"Whitelaw","year":"2019","journal-title":"Endocr Relat Cancer"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2010-0441","article-title":"Temozolomide Treatment for Aggressive Pituitary Tumors: Correlation of Clinical Outcome With O(6)-Methylguanine Methyltransferase (MGMT) Promoter Methylation and Expression","volume":"95","author":"Bush","year":"2010","journal-title":"J Clin Endocrinol Metab"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2013.49.6968","article-title":"Dose-Dense Temozolomide for Newly Diagnosed Glioblastoma: A Randomized Phase III Clinical Trial","volume":"31","author":"Gilbert","year":"2013","journal-title":"J Clin Oncol"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa043330","article-title":"Radiotherapy Plus Concomitant and Adjuvant Temozolomide for Glioblastoma","volume":"352","author":"Stupp","year":"2005","journal-title":"N Engl J Med"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1530\/EJE-17-0933","article-title":"Treatment of Aggressive Pituitary Tumours and Carcinomas: Results of a European Society of Endocrinology (ESE) Survey 2016","volume":"178","author":"McCormack","year":"2018","journal-title":"Eur J Endocrinol"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2014-4350","article-title":"Long-Term Outcome and MGMT as a Predictive Marker in 24 Patients With Atypical Pituitary Adenomas and Pituitary Carcinomas Given Treatment With Temozolomide","volume":"100","author":"Bengtsson","year":"2015","journal-title":"J Clin Endocrinol Metab"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgz211","article-title":"Efficacy of Temozolomide Therapy in Patients With Aggressive Pituitary Adenomas and Carcinomas-A German Survey","volume":"105","author":"Elbelt","year":"2020","journal-title":"J Clin Endocrinol Metab"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1093\/nop\/npv059","article-title":"Temozolomide Treatment of Pituitary Carcinomas and Atypical Adenomas: Systematic Review of Case Reports","volume":"3","author":"Ji","year":"2016","journal-title":"Neurooncol Pract"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1530\/EJE-16-0979","article-title":"Temozolomide Treatment Can Improve Overall Survival in Aggressive Pituitary Tumors and Pituitary Carcinomas","volume":"176","author":"Lasolle","year":"2017","journal-title":"Eur J Endocrinol"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1007\/s11102-020-01040-4","article-title":"Long-Course Temozolomide in Aggressive Pituitary Adenoma: Real-Life Experience in Two Tertiary Care Centers and Review of the Literature","volume":"23","author":"Lizzul","year":"2020","journal-title":"Pituitary"},{"key":"B45","doi-asserted-by":"publisher","first-page":"E447","DOI":"10.1227\/NEU.0000000000000251","article-title":"High Response Rates and Prolonged Survival in Patients With Corticotroph Pituitary Tumors and Refractory Cushing Disease From Capecitabine and Temozolomide (CAPTEM): A Case Series","volume":"74","author":"Zacharia","year":"2014","journal-title":"Neurosurgery"},{"key":"B46","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1186\/1476-4598-5-67","article-title":"Analysis of Gene Expression and Chemoresistance of CD133+ Cancer Stem Cells in Glioblastoma","volume":"5","author":"Liu","year":"2006","journal-title":"Mol Cancer"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2362.2011.02520.x","article-title":"Aggressive Pituitary Tumours: The Role of Temozolomide and the Assessment of MGMT Status","volume":"41","author":"McCormack","year":"2011","journal-title":"Eur J Clin Invest"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1530\/EJE-09-0389","article-title":"Temozolomide Treatment of a Pituitary Carcinoma and Two Pituitary Macroadenomas Resistant to Conventional Therapy","volume":"161","author":"Hagen","year":"2009","journal-title":"Eur J Endocrinol"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1007\/s11102-011-0363-7","article-title":"Temozolomide Responsiveness in Aggressive Corticotroph Tumours: A Case Report and Review of the Literature","volume":"15","author":"Annamalai","year":"2012","journal-title":"Pituitary"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1007\/s11060-015-1991-y","article-title":"Temozolomide Therapy in Patients With Aggressive Pituitary Adenomas or Carcinomas","volume":"126","author":"Losa","year":"2016","journal-title":"J Neurooncol"},{"key":"B51","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1210\/er.2013-1048","article-title":"The Treatment of Cushing's Disease","volume":"36","author":"Pivonello","year":"2015","journal-title":"Endocr Rev"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1007\/s11060-014-1702-0","article-title":"Temozolomide and Pasireotide Treatment for Aggressive Pituitary Adenoma: Expertise at a Tertiary Care Center","volume":"122","author":"Ceccato","year":"2015","journal-title":"J Neurooncol"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1007\/s11102-016-0755-9","article-title":"Paradoxical and Atypical Responses to Pasireotide in Aggressive ACTH-Secreting Pituitary Tumors","volume":"19","author":"Greenman","year":"2016","journal-title":"Pituitary"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2013-1497","article-title":"Sustained Improvements in Plasma ACTH and Clinical Status in a Patient With Nelson's Syndrome Treated With Pasireotide LAR, a Multireceptor Somatostatin Analog","volume":"98","author":"Katznelson","year":"2013","journal-title":"J Clin Endocrinol Metab"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgz200","article-title":"Outcomes of Patients With Nelson's Syndrome After Primary Treatment: A Multicenter Study From 13 UK Pituitary Centers","volume":"105","author":"Fountas","year":"2020","journal-title":"J Clin Endocrinol Metab"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1007\/s11102-017-0853-3","article-title":"A Prospective Longitudinal Study of Pasireotide in Nelson's Syndrome","volume":"21","author":"Daniel","year":"2018","journal-title":"Pituitary"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1007\/s40618-020-01335-0","article-title":"Somatostatin Receptor Expression and Patients' Response to Targeted Medical Treatment in Pituitary Tumors: Evidences and Controversies","volume":"43","author":"Gatto","year":"2020","journal-title":"J Endocrinol Invest"},{"key":"B58","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1530\/eje.0.1410396","article-title":"Somatostatin and Its Analog Lanreotide Inhibit the Proliferation of Dispersed Human Non-Functioning Pituitary Adenoma Cells In Vitro","volume":"141","author":"Florio","year":"1999","journal-title":"Eur J Endocrinol"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1007\/s11102-011-0370-8","article-title":"Treatment With Octreotide LAR in Clinically Non-Functioning Pituitary Adenoma: Results From a Case-Control Study","volume":"15","author":"Fusco","year":"2012","journal-title":"Pituitary"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1677\/ERC-08-0181","article-title":"Medical Therapy for Clinically Non-Functioning Pituitary Adenomas","volume":"15","author":"Colao","year":"2008","journal-title":"Endocr Relat Cancer"},{"key":"B61","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1677\/ERC-06-0026","article-title":"Pasireotide, a Multiple Somatostatin Receptor Subtypes Ligand, Reduces Cell Viability in Non-Functioning Pituitary Adenomas by Inhibiting Vascular Endothelial Growth Factor Secretion","volume":"14","author":"Zatelli","year":"2007","journal-title":"Endocr Relat Cancer"},{"key":"B62","doi-asserted-by":"publisher","first-page":"3052","DOI":"10.3390\/jcm9093052","article-title":"Quantitative Analysis of Somatostatin and Dopamine Receptors Gene Expression Levels in Non-Functioning Pituitary Tumors and Association With Clinical and Molecular Aggressiveness Features","volume":"9","author":"Flores-Martinez","year":"2020","journal-title":"J\u00a0Clin Med"},{"key":"B63","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1530\/EJE-07-0806","article-title":"Somatostatinergic Ligands in Dopamine-Sensitive and -Resistant Prolactinomas","volume":"158","author":"Fusco","year":"2008","journal-title":"Eur J Endocrinol"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1007\/s12020-018-1638-9","article-title":"Treatment of Multiresistant Prolactinomas With a Combination of Cabergoline and Octreotide LAR","volume":"61","author":"Sosa-Eroza","year":"2018","journal-title":"Endocrine"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1530\/EJE-19-0279","article-title":"Excellent Response to Pasireotide Therapy in an Aggressive and Dopamine-Resistant Prolactinoma","volume":"181","author":"Coopmans","year":"2019","journal-title":"Eur J Endocrinol"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1530\/EJE-19-0359","article-title":"Confirmation of a New Therapeutic Option for Aggressive or Dopamine Agonist-Resistant Prolactin Pituitary Neuroendocrine Tumors","volume":"181","author":"Raverot","year":"2019","journal-title":"Eur J Endocrinol"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1055\/a-1060-1883","article-title":"Management of Aggressive Pituitary Tumors - A 2019 Update","volume":"51","author":"Petersenn","year":"2019","journal-title":"Horm Metab Res"},{"key":"B68","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.3390\/jcm8081107","article-title":"Emerging and Novel Treatments for Pituitary Tumors","volume":"8","author":"Ilie","year":"2019","journal-title":"J Clin Med"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1530\/ERC-11-0066","article-title":"Expression and Function of ErbB Receptors and Ligands in the Pituitary","volume":"18","author":"Cooper","year":"2011","journal-title":"Endocr Relat Cancer"},{"key":"B70","doi-asserted-by":"publisher","first-page":"2270","DOI":"10.12688\/f1000research.9025.1","article-title":"EGF Receptor Ligands: Recent Advances","volume":"5","author":"Singh","year":"2016","journal-title":"F1000Res"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.1172\/JCI60417","article-title":"EGFR as a Therapeutic Target for Human, Canine, and Mouse ACTH-Secreting Pituitary Adenomas","volume":"121","author":"Fukuoka","year":"2011","journal-title":"J Clin Invest"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.1007\/s11102-015-0637-6","article-title":"New Potential Targets for Treatment of Cushing's Disease: Epithelial Growth Factor Receptor and Cyclin-Dependent Kinases","volume":"18","author":"Fukuoka","year":"2015","journal-title":"Pituitary"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.1038\/cr.2015.20","article-title":"Recurrent Gain-of-Function USP8 Mutations in Cushing's Disease","volume":"25","author":"Ma","year":"2015","journal-title":"Cell Res"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.1038\/ng.3166","article-title":"Mutations in the Deubiquitinase Gene USP8 Cause Cushing's Disease","volume":"47","author":"Reincke","year":"2015","journal-title":"Nat Genet"},{"key":"B75","doi-asserted-by":"publisher","first-page":"E997","DOI":"10.1210\/jc.2015-1453","article-title":"The Gene of the Ubiquitin-Specific Protease 8 Is Frequently Mutated in Adenomas Causing Cushing's Disease","volume":"100","author":"Perez-Rivas","year":"2015","journal-title":"J Clin Endocrinol Metab"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/noz109","article-title":"Driver Mutations in USP8 Wild-Type Cushing's Disease","volume":"21","author":"Sbiera","year":"2019","journal-title":"Neuro Oncol"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.1530\/EJE-15-0689","article-title":"The USP8 Mutational Status may Predict Drug Susceptibility in Corticotroph Adenomas of Cushing's Disease","volume":"174","author":"Hayashi","year":"2016","journal-title":"Eur J Endocrinol"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2017-00161","article-title":"Somatic USP8 Gene Mutations Are a Common Cause of Pediatric Cushing Disease","volume":"102","author":"Faucz","year":"2017","journal-title":"J Clin Endocrinol Metab"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.1111\/cen.13802","article-title":"The USP8 Mutational Status may Predict Long-Term Remission in Patients With Cushing's Disease","volume":"89","author":"Albani","year":"2018","journal-title":"Clin Endocrinol (Oxf)"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgaa853","article-title":"USP8 and TP53 Drivers Are Associated With CNV in a Corticotroph Adenoma Cohort Enriched for Aggressive Tumors","volume":"106","author":"Uzilov","year":"2021","journal-title":"J Clin Endocrinol Metab"},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2019.00785","article-title":"Expression of EGFR in Pituitary Corticotroph Adenomas and Its Relationship With Tumor Behavior","volume":"10","author":"Liu","year":"2019","journal-title":"Front Endocrinol (Lausanne)"},{"key":"B82","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1210\/me.2010-0353","article-title":"HER2\/ErbB2 Receptor Signaling in Rat and Human Prolactinoma Cells: Strategy for Targeted Prolactinoma Therapy","volume":"25","author":"Fukuoka","year":"2011","journal-title":"Mol Endocrinol"},{"key":"B83","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-08-4934","article-title":"Heregulin Regulates Prolactinoma Gene Expression","volume":"69","author":"Vlotides","year":"2009","journal-title":"Cancer Res"},{"key":"B84","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1007\/BF02739952","article-title":"Adrenocorticotropin-Producing Pituitary Carcinoma With Expression of c-erbB-2 and High PCNA Index: A Comparative Study With Pituitary Adenomas and Normal Pituitary Tissues","volume":"9","author":"Nose-Alberti","year":"1998","journal-title":"Endocr Pathol"},{"key":"B85","doi-asserted-by":"publisher","DOI":"10.1007\/s12020-013-0093-x","article-title":"Prolactinoma ErbB Receptor Expression and Targeted Therapy for Aggressive Tumors","volume":"46","author":"Cooper","year":"2014","journal-title":"Endocrine"},{"key":"B86","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgaa805","article-title":"EGFR\/ErbB2-Targeting Lapatinib Therapy for Aggressive Prolactinomas","volume":"106","author":"Cooper","year":"2021","journal-title":"J Clin Endocrinol Metab"},{"key":"B87","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.30628","article-title":"Complementary Actions of Dopamine D2 Receptor Agonist and Anti-Vegf Therapy on Tumoral Vessel Normalization in a Transgenic Mouse Model","volume":"140","author":"Chauvet","year":"2017","journal-title":"Int J Cancer"},{"key":"B88","doi-asserted-by":"publisher","first-page":"608497","DOI":"10.1155\/2014\/608497","article-title":"Angiogenesis in Pituitary Adenomas: Human Studies and New Mutant Mouse Models","volume":"2014","author":"Cristina","year":"2014","journal-title":"Int J Endocrinol"},{"key":"B89","doi-asserted-by":"publisher","DOI":"10.1055\/a-1260-3975","article-title":"Bevacizumab in Aggressive Pituitary Adenomas - Experience With 3 Patients","volume":"129","author":"Osterhage","year":"2021","journal-title":"Exp Clin Endocrinol Diabetes"},{"key":"B90","doi-asserted-by":"publisher","DOI":"10.1007\/s11102-011-0346-8","article-title":"Anti-VEGF Therapy in Pituitary Carcinoma","volume":"15","author":"Ortiz","year":"2012","journal-title":"Pituitary"},{"key":"B91","doi-asserted-by":"publisher","DOI":"10.1016\/j.jocn.2017.02.052","article-title":"Successful Treatment of Pituitary Carcinoma With Concurrent Radiation, Temozolomide, and Bevacizumab After Resection","volume":"41","author":"Touma","year":"2017","journal-title":"J Clin Neurosci"},{"key":"B92","doi-asserted-by":"publisher","DOI":"10.1016\/j.wneu.2018.11.011","article-title":"Long-Term Survival After Transformation of an Adrenocorticotropic Hormone-Secreting Pituitary Macroadenoma to a Silent Corticotroph Pituitary Carcinoma","volume":"122","author":"Rotman","year":"2019","journal-title":"World Neurosurg"},{"key":"B93","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1530\/EJE-18-0795","article-title":"Treatment and Long-Term Outcomes in Pituitary Carcinoma: A Cohort Study","volume":"181","author":"Santos-Pinheiro","year":"2019","journal-title":"Eur J Endocrinol"},{"key":"B94","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2009-1641","article-title":"Effect of Everolimus on Cell Viability in Nonfunctioning Pituitary Adenomas","volume":"95","author":"Zatelli","year":"2010","journal-title":"J Clin Endocrinol Metab"},{"key":"B95","doi-asserted-by":"publisher","DOI":"10.1007\/s12022-019-9568-5","article-title":"An Institutional Experience of Tumor Progression to Pituitary Carcinoma in a 15-Year Cohort of 1055 Consecutive Pituitary Neuroendocrine Tumors","volume":"30","author":"Alshaikh","year":"2019","journal-title":"Endocr Pathol"},{"key":"B96","doi-asserted-by":"publisher","DOI":"10.2217\/cns-2016-0011","article-title":"Widely Metastatic Atypical Pituitary Adenoma With mTOR Pathway STK11(F298L) Mutation Treated With Everolimus Therapy","volume":"5","author":"Donovan","year":"2016","journal-title":"CNS Oncol"},{"key":"B97","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2018-02461","article-title":"Effect of Everolimus in Treatment of Aggressive Prolactin-Secreting Pituitary Adenomas","volume":"104","author":"Zhang","year":"2019","journal-title":"J Clin Endocrinol Metab"},{"key":"B98","doi-asserted-by":"publisher","first-page":"30","DOI":"10.3390\/jcm9010030","article-title":"The Genetics of Pituitary Adenomas","volume":"9","author":"Tatsi","year":"2019","journal-title":"J Clin Med"}],"container-title":["Frontiers in Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2021.725014\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,11,15]],"date-time":"2021-11-15T06:33:48Z","timestamp":1636958028000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2021.725014\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11,15]]},"references-count":98,"alternative-id":["10.3389\/fendo.2021.725014"],"URL":"https:\/\/doi.org\/10.3389\/fendo.2021.725014","relation":{},"ISSN":["1664-2392"],"issn-type":[{"value":"1664-2392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,11,15]]},"article-number":"725014"}}